A dose‐ranging study of ticagrelor in children aged 3‐17 years with sickle cell disease: A 2‐part phase 2 study

Antiplatelet treatment is a potential therapeutic approach for sickle cell disease (SCD). Ticagrelor inhibits platelet aggregation and is approved for adults with acute coronary syndrome and following myocardial infarction. HESTIA1 (NCT02214121) was a 2‐part, phase 2 dose‐finding study generating ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Lewis L., Sarnaik, Sharada, Williams, Suzan, Amilon, Carl, Wissmar, Jenny, Berggren, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282821/
https://www.ncbi.nlm.nih.gov/pubmed/30187935
http://dx.doi.org/10.1002/ajh.25273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282821/
https://www.ncbi.nlm.nih.gov/pubmed/30187935
http://dx.doi.org/10.1002/ajh.25273

Ejemplares similares